Search Result

Results for "

hepatic bile acid

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apical Sodium-Dependent Bile Acid Transporter (1) G protein-coupled Bile Acid Receptor 1 (4) Angiotensin-converting Enzyme (ACE) (2) Atg8/LC3 (1) Autophagy (1) Biochemical Assay Reagents (1) Cytochrome P450 (2) Endogenous Metabolite (8) Fluorescent Dye (1) FXR (5) HBV (1) Isotope-Labeled Compounds (2) MMP (1) P-glycoprotein (1) p62 (1) Phosphatase (1) TGF-beta/Smad (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (1) Infection (4) Inflammation/Immunology (4) Metabolic Disease (10)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Apical Sodium-Dependent Bile Acid Transporter G protein-coupled Bile Acid Receptor 1 Amino acid Transporter Amino Acid Derivatives Hydroxycarboxylic Acid Receptor (HCAR) Free Fatty Acid Receptor Fatty Acid Synthase (FASN)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13771A

Ursodeoxycholic acid sodium Maximum Cited Publications 13 Publications Verification Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium	G protein-coupled Bile Acid Receptor 1 FXR Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Cancer
Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid sodium can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .

HY-13771

Ursodeoxycholic acid Maximum Cited Publications 13 Publications Verification Ursodeoxycholate; Ursodiol; UDCA	G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite	Infection Metabolic Disease Cancer
Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-113315

3b-Hydroxy-5-cholenoic acid	Endogenous Metabolite	Metabolic Disease
3b-Hydroxy-5-cholenoic acid is a monohydroxy bile acid of endogenous origin and could be found in children with the syndrome of hepatic ductular hypoplasia.

HY-113478

3β-Ursodeoxycholic acid 1 Publications Verification Isoursodeoxycholic acid	Others	Metabolic Disease
3β-Ursodeoxycholic acid (Isoursodeoxycholic acid) is a bile acid. 3β-Ursodeoxycholic acid shows good tolerance and well intestinal absorption by oral adminstation. 3β-Ursodeoxycholic acid can be isomerized by intestinal and hepatic enzymes to yield UDCA .

HY-113360

Chenodeoxycholic acid 3-sulfate	Endogenous Metabolite	Inflammation/Immunology
Chenodeoxycholic acid 3-sulfate is a bile acid. Chenodeoxycholic acid 3-sulfate level corresponds closely with the extent of hepatic dysfunction .

HY-13771R

Ursodeoxycholic acid (Standard)	G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite	Infection Metabolic Disease Cancer
Ursodeoxycholic acid (Standard) is the analytical standard of Ursodeoxycholic acid. This product is intended for research and analytical applications. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-168524

SOAT-IN-1	Others	Cancer
SOAT-IN-1 (compound 40) is a potent and selective sodium-dependent organic anion transporter (SOAT) inhibitor with IC₅₀ values of 1.6, 14.3 µM for SOAT, NTCP, respectively .

HY-105047

Fluorescein lisicol NRL972	Biochemical Assay Reagents	Metabolic Disease
Fluorescein lisicol is a fluorescent-labelled bile salt and a marker of hepatic biliary transporter function. Fluorescein lisicol can be used for metabolic research .

HY-W779068

Chenodeoxycholic acid 3-sulfate disodium	Endogenous Metabolite	Inflammation/Immunology
Chenodeoxycholic acid 3-sulfate disodium is a bile acid. Chenodeoxycholic acid 3-sulfate disodium level corresponds closely with the extent of hepatic dysfunction .

HY-169799

Cholylglycylamidofluorescein CGamF	Endogenous Metabolite Fluorescent Dye	Metabolic Disease
Cholylglycylamidofluorescein (CGamF) is a fluorescent probe for hepatic bile acid transport. Cholylglycylamidofluorescein is composed of Cholic acid conjugated via a glycylamino linkage to fluorescein. (Ex/Em = 492/515 nM in Aqueous)

HY-13771S1

Ursodeoxycholic acid-13C Ursodeoxycholate-¹³C; Ursodiol-¹³C; UDCA-¹³C	Isotope-Labeled Compounds G protein-coupled Bile Acid Receptor 1 FXR Endogenous Metabolite	Cancer
Ursodeoxycholic acid- ¹³C is the ¹³C labeled Ursodeoxycholic acid. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active[1][2].

HY-129982

SC-435	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
SC-435 is an orally effective *apical sodium codependent bile* acid transporter (ASBT)** inhibitor. SC-435 effectively removes neurotoxic bile acids and ammonia from the blood by inhibiting intestinal ASBT, thereby alleviating liver and brain damage caused by liver failure. SC-435 can alter hepatic cholesterol metabolism and lower plasma low-density lipoprotein-cholesterol concentrations .

HY-113478S

Ursodeoxycholic acid-2,2,4,4-d4	Isotope-Labeled Compounds	Infection Metabolic Disease
Ursodeoxycholic acid-2,2,4,4-d₄ is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection[1][2][3][4][5].

HY-N13208

Stevia Powder	MMP TGF-beta/Smad	Others
Stevia Powder is a natural sweetener with antioxidant activity. Stevia Powder can downregulate pro fibrotic pathways in cirrhotic rats, including reduced hepatic myofibroblasts and decreased expression of matrix metalloproteinases MMP2 and MMP13, upregulate anti fibrotic molecule Smad7, prevent serum necrosis and elevated bile stasis markers, thereby inhibiting the development of liver fibrosis .

HY-113478R

3β-Ursodeoxycholic acid (Standard)	Others	Metabolic Disease
3β-Ursodeoxycholic acid (Standard) is the analytical standard of 3β-Ursodeoxycholic acid. This product is intended for research and analytical applications. 3β-Ursodeoxycholic acid (Isoursodeoxycholic acid) is a bile acid. 3β-Ursodeoxycholic acid shows good tolerance and well intestinal absorption by oral adminstation. 3β-Ursodeoxycholic acid can be isomerized by intestinal and hepatic enzymes to yield UDCA .

HY-W018791

Bifendate DDB	HBV Autophagy Cytochrome P450 Atg8/LC3 p62 P-glycoprotein	Infection Cardiovascular Disease Cancer
Bifendate (DDB), extracted from Schisandrae chinensis, is an orally active anti-HBV agent against chronic hepatitis B. Bifendate inhibits ATG5-dependent autophagy and attenuates oleic acid-induced lipid accumulation with anti-oxidant properties in vitro. Bifendate can decrease alanine transaminase (ALT) level in mice. Bifendate attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. Bifendate potently increases the activity of cytochrome proteins (CYPs) and reverse P-gp-mediated multi-drug resistance (MDR) .

HY-134988

EDP-305	FXR Phosphatase Cytochrome P450	Inflammation/Immunology
EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC₅₀ values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 shows a potent and consistent antifibrotic effect. EDP-305 can be used for primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-13771A

Ursodeoxycholic acid sodium 10+ Cited Publications Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium	Structural Classification Microorganisms Classification of Application Fields Source classification Metabolic Disease Inflammation/Immunology Disease Research Fields Steroids	G protein-coupled Bile Acid Receptor 1 FXR Endogenous Metabolite
Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid sodium can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .

HY-13771

Ursodeoxycholic acid 10+ Cited Publications Ursodeoxycholate; Ursodiol; UDCA	Structural Classification Human Gut Microbiota Metabolites Microorganisms Other disease Classification of Application Fields Source classification Disease markers Endogenous metabolite Disease Research Fields Steroids Cancer	G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-113315

3b-Hydroxy-5-cholenoic acid	Structural Classification Microorganisms Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
3b-Hydroxy-5-cholenoic acid is a monohydroxy bile acid of endogenous origin and could be found in children with the syndrome of hepatic ductular hypoplasia.

HY-113360

Chenodeoxycholic acid 3-sulfate	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields Steroids	Endogenous Metabolite
Chenodeoxycholic acid 3-sulfate is a bile acid. Chenodeoxycholic acid 3-sulfate level corresponds closely with the extent of hepatic dysfunction .

HY-13771R

Ursodeoxycholic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Other disease Source classification Disease markers Endogenous metabolite Steroids	G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Ursodeoxycholic acid (Standard) is the analytical standard of Ursodeoxycholic acid. This product is intended for research and analytical applications. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-W779068

Chenodeoxycholic acid 3-sulfate disodium	Structural Classification Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields Steroids	Endogenous Metabolite
Chenodeoxycholic acid 3-sulfate disodium is a bile acid. Chenodeoxycholic acid 3-sulfate disodium level corresponds closely with the extent of hepatic dysfunction .

Cat. No.	Product Name	Chemical Structure

HY-113478S

Ursodeoxycholic acid-2,2,4,4-d4
Ursodeoxycholic acid-2,2,4,4-d₄ is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection[1][2][3][4][5].

Ursodeoxycholic acid-2,2,4,4-d4

Ursodeoxycholic acid-2,2,4,4-d₄ is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection[1][2][3][4][5].

HY-13771S1

Ursodeoxycholic acid-13C
Ursodeoxycholic acid- ¹³C is the ¹³C labeled Ursodeoxycholic acid. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active[1][2].

Ursodeoxycholic acid-13C

Ursodeoxycholic acid- ¹³C is the ¹³C labeled Ursodeoxycholic acid. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

hepatic bile acid

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Natural
Products